Although most GI irAEs are relatively mild, 15–20% of patients receiving CTLA-4 inhibitors and 2–5% of patients receiving PD-1/PD-L1 inhibitors will develop severe enterocolitis, with a smaller fraction progressing to life-threatening inflammation (Table 1) [14,18,19]. Here, CTLA4 is linked to enterocolitis.